Download PDF Version - ExpertFile

Dr. David Jaffray
Executive Vice President, Technology and Innovation at University Health Network
Toronto, ON, CA
Focusing on the development of novel approaches of targeting & applying radiation therapy & translating these
advances to clinical practice
Description
Following graduation, Dr. Jaffray took a position as staff physicist in the Department of Radiation Oncology at
William Beaumont Hospital, Royal Oak, Michigan, where he instigated a direction of research that garnered
funding from the National Institutes of Health (NIH) and from congressionally directed funding programs. Dr.
Jaffray became a Board Certified Medical Physicist (ABMP - Radiation Oncology) in 1999. In 2002, Dr.
Jaffray joined the Princess Margaret Hospital as Head of Radiation Physics and a Senior Scientist within the
Ontario Cancer Institute. He holds the Fidani Chair in Radiation Physics and is a principal in the STTARR
Innovation Centre and Guided Therapeutics (GTx) Group of the University Health Network. He is the interim
director of the recently established Institute of Health Technology Development at the University Health
Network. He is a professor in the Departments of Radiation Oncology, Medical Biophysics, and Institute for
Biomaterials and Biomedical Engineering at the University of Toronto.
Dr. Jaffray's primary area of research over the past 10 years has been the development and application of imageguided radiation therapy. He has over 5 patents issued and several licensed, including kilovoltage cone-beam
computed tomography for image-guided radiation therapy. Dr. Jaffray has in excess of 120 peer-reviewed
publications in the field, in excess of 100 invited lectures, and holds numerous peer-review and industry
sponsored research grants. He sits on numerous scientific and research boards and has contributed to the NIH
and CIHR grant review process for several years. He is a member at large of the Science Council of the
American Association of Physicists in Medicine and has an active teaching role in workshops and annual
meetings of the American Society of Therapeutic Radiation Oncology. He has an active interest in
commercialization and led the development of a variety of commercial products, including software and
hardware for quality assurance and the development of small-animal irradiator systems for basic research. He
has successfully supervised over 20 graduate students and fellows. Dr. Jaffray has won each of the major prizes
in the field of medical physics, including the Sylvia Sorkin-Greenfield Award, the Farrington Daniels and the
Sylvia Fedoruk Award. In 2004, Dr. Jaffray was identified as one of Canada's Top 40 Under 40 and was
recognized by the University of Western Ontario with its Young Alumni Award in 2004.
Industry Expertise
Health and Wellness, Health Care - Providers, Health Care - Services, Research
Topics
Radiation Physics, Staarr Facility, Technology Transfer, Image-Guidance, Radiation Therapy, Cone-Beam Ct,
X-Ray Imaging
Affiliations
Head, Radiation Physics Department, Princess Margaret Hospital, University Health Network , Director,
Techna Institute, University Health Network, Fidani Chair in Radiation Therapy Physics, University of
Toronto, Senior Scientist, Ontario Cancer Institute, Vice Chair and Professor, Departments of Radiation
Oncology and Medical Biophysics, University of Toronto
Education
University of Alberta
1988
BSc Physics
University of Western Ontario
1994
PhD Department of Medical Biophysics
Media Appearances
Dr. David Jaffray was Recently Awarded $1.84 Million over Four Years for Quantitative Imaging
Princess Margaret Hospital
2012-05-03
Personalized Cancer Medicine is ever closer as Princess Margaret's Dr. David Jaffray was recently awarded
$1.84 million over four years from the Ontario Institute for Cancer Research for the project "Quantitative
Imaging for Personalized Cancer Medicine".
UHN, U of T Launch Techna Innovation Hub to Get Health Technologies to Patients Faster
University Health Network
2011-11-09
The Techna Institute, an innovation hub poised to integrate and fast track research, development and
commercialization of new healthcare technologies, launches today at University Health Network (UHN) and
the University of Toronto (U of T).
Princess Margaret Leads Radiotherapy Task Force
University Health Network
2014-03-14
Princess Margaret Cancer Centre is leading a new international Global Task Force on Radiotherapy for Cancer
Control (GTFRCC) to tackle lack of access to treatment in countries that most need it.
Dr. David Jaffray, Head, UHN Radiation and Imaging Physics and Director, Techna Institute, is leading the
GTFRCC Secretariat, which was officially announced Feb. 5 at the cancer centre on behalf of the Union for
International Cancer Control (UICC).
Articles
A framework for noise-power spectrum analysis of multidimensional images
PubMed.gov
2002-11-01
A methodological framework for experimental analysis of the noise-power spectrum (NPS) of
multidimensional images is presented that employs well-known properties of the n-dimensional (nD) Fourier
transform.
Flat-panel cone-beam computed tomography for image-guided radiation therapy
PubMed.gov
2002-08-01
Geometric uncertainties in the process of radiation planning and delivery constrain dose escalation and induce
normal tissue complications. An imaging system has been developed to generate high-resolution, soft-tissue
images of the patient at the time of treatment for the purpose of guiding therapy and reducing such
uncertainties. The performance of the imaging system is evaluated and the application to image-guided
radiation therapy is discussed.
A performance comparison of flat-panel imager-based MV and kV cone-beam CT
PubMed.gov
2002-06-01
The use of cone-beam computed tomography (CBCT) has been proposed for guiding the delivery of radiation
therapy, and investigators have examined the use of both kilovoltage (kV) and megavoltage (MV) x-ray beams
in the development of such CBCT systems. In this paper, the inherent contrast and signal-to-noise ratio (SNR)
performance for a variety of existing and hypothetical detectors for CBCT are investigated analytically as a
function of imaging dose and object size. Theoretical predictions are compared to the results of experimental
investigations employing largearea flat-panel imagers (FPIs) at kV and MV energies. Measurements were
performed on two different FPI-based CBCT systems: a bench-top prototype incorporating an FPI and kV x-ray
source (100 kVp x rays), and a system incorporating an FPI mounted on the gantry of a medical linear
accelerator (6 MV x rays). The SNR in volume reconstructions was measured as a function of dose and found
to agree reasonably with theoretical predictions. These results confirm the theoretically predicted advantages of
employing kV energy x rays in imaging soft-tissue structures found in the human body. While MV CBCT may
provide a valuable means of correcting 3D setup errors and may offer an advantage in terms of simplicity of
mechanical integration with a linear accelerator (e.g., implementation in place of a portal imager), kV CBCT
offers significant performance advantages in terms of image contrast and SNR per unit dose for visualization of
soft-tissue structures. The relatively poor SNR performance at MV energies is primarily a result of the low xray quantum efficiencies (approximately a few percent or less) that are currently achieved with FPIs at high
energies. Furthermore, kV CBCT with an FPI offers the potential of combined volumetric and
radiographic/fluoroscopic imaging using the same device.
Integration of optical imaging with a small animal irradiator
PubMed.gov
2014-10-01
The authors describe the integration of optical imaging with a targeted small animal irradiator device, focusing
on design, instrumentation, 2D to 3D image registration, 2D targeting, and the accuracy of recovering and
mapping the optical signal to a 3D surface generated from the cone-beam computed tomography (CBCT)
imaging. The integration of optical imaging will improve targeting of the radiation treatment and offer
longitudinal tracking of tumor response of small animal models treated using the system.
MR-guided Prostate Biopsy for Planning of Focal Salvage after Radiation Therapy
PubMed.gov
2014-09-01
Purpose To determine if the integration of diagnostic magnetic resonance (MR) imaging and MR-guided
biopsy would improve target delineation for focal salvage therapy in men with prostate cancer. Materials and
Methods Between September 2008 and March 2011, 30 men with biochemical failure after radiation therapy
for prostate cancer provided written informed consent and were enrolled in a prospective clinical trial approved
by the institutional research ethics board.
Please click here to view the full profile.
This profile was created by ExpertFile.